SCHEMBL1744932

SCHEMBL1744932

COC(=O)CCc1ccc(OCc2ccccc2Cc2ccccc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 15/20 0.56
FFAR4 Q5NUL3 9/20 0.56
LTA4H P09960 2/20 0.55
AKR1B1 P15121 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14305720 0.88 FFAR1 (0.67) FFAR1FFAR4LTA4HAKR1B1
SCHEMBL1745273 0.87 FFAR1 (0.73) FFAR1FFAR4AKR1B1
SCHEMBL1747136 0.86 FFAR1 (0.72) FFAR1FFAR4LTA4HAKR1B1
SCHEMBL1745247 0.86 FFAR1 (0.72) FFAR1FFAR4LTA4HAKR1B1
SCHEMBL12158542 0.84 FFAR1 (0.50) FFAR1FFAR4AKR1B1
SCHEMBL1745420 0.84 FFAR1 (0.60) FFAR1FFAR4LTA4HAKR1B1
SCHEMBL1747337 0.84 FFAR1 (0.77) FFAR1FFAR4
SCHEMBL28556161 0.83 MAOB (0.60) FFAR1FFAR4AKR1B1
SCHEMBL1745237 0.83 FFAR1 (0.70) FFAR1FFAR4AKR1B1
SCHEMBL1745645 0.82 FFAR1 (0.77) FFAR1FFAR4AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR FFAR1 33/4885FFAR4 44/4885LTA4H 1978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.